Skip to content
Alvimopan
Entereg (alvimopan) is a small molecule pharmaceutical. Alvimopan was first approved as Entereg on 2008-05-20. It is known to target mu-type opioid receptor, delta-type opioid receptor, and kappa-type opioid receptor.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Entereg (generic drugs available since 2019-12-19)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Alvimopan
Tradename
Company
Number
Date
Products
ENTEREGCubist PharmaceuticalsN-021775 RX2008-05-20
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
alvimopanANDA2023-04-26
enteregNew Drug Application2020-11-17
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Alvimopan, Entereg, Cubist Pharms
89462622030-02-12U-1655
ATC Codes
A: Alimentary tract and metabolism drugs
A06: Drugs for constipation
A06A: Drugs for constipation
A06AH: Peripheral opioid receptor antagonists
A06AH02: Alvimopan
HCPCS
No data
Clinical
Clinical Trials
28 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cardiopulmonary bypassD00231511
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Multiple sclerosisD009103EFO_0003885G3511
ChickenpoxD002644EFO_0007204B0111
Healthy volunteers/patients11
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Squamous cell carcinoma of head and neckD000077195213
Myelodysplastic syndromesD009190D46112
Myeloid leukemia acuteD015470C92.0112
Non-small-cell lung carcinomaD002289112
Prostatic neoplasmsD011471C61112
Kaposi sarcomaD012514C4622
Myelomonocytic leukemia chronicD015477C93.111
Chemotherapy-induced febrile neutropeniaD06414611
Urologic neoplasmsD014571C64-C6811
Head and neck neoplasmsD00625811
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
MalariaD008288EFO_0001068B54112
Urinary bladder neoplasmsD001749C6722
Pancreatic neoplasmsD010190EFO_0003860C2511
Gallbladder neoplasmsD005706EFO_0004606C2311
Relapsing-remitting multiple sclerosisD020529EFO_000392911
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.011
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011
Philadelphia chromosomeD01067711
SarcomaD01250911
LymphomaD008223C85.911
Show 2 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfertilityD007246EFO_000054522
Fertilization in vitroD00530711
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameALVIMOPAN
INNalvimopan
Description
Alvimopan is a peptide.
Classification
Small molecule
Drug class
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1
Identifiers
PDB
CAS-ID156053-89-3
RxCUI1516803
ChEMBL IDCHEMBL270190
ChEBI ID
PubChem CID5488548
DrugBankDB06274
UNII IDQ153V49P3Z (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
OPRM1
OPRM1
OPRD1
OPRD1
OPRK1
OPRK1
Organism
Homo sapiens
Gene name
OPRM1
Gene synonyms
MOR1
NCBI Gene ID
Protein name
mu-type opioid receptor
Protein synonyms
hMOP, MOP, Mu opiate receptor, Mu opioid receptor, mu opioid receptor hMOR-1a
Uniprot ID
Mouse ortholog
Oprm1 (18390)
mu-type opioid receptor (P42866)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 535 documents
View more details
Safety
Black-box Warning
Black-box warning for: Alvimopan, Entereg
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
15 adverse events reported
View more details